Ferrero, S., Ladetto, M., Beldjord, K., Drandi, D., Stelitano, C., Bernard, S., Castagnari, B., Bouabdallah, K., Cesaretti, M., Alvarez, I., Gressin, R., Ponzoni, M., Tripodo, C., Traverse‐Glehen, A., Baseggio, L., Liberati, A., Merli, M., Tessoulin, B., Patti, C., Cabras, M., Feugier, P., Pozzi, S., Zucca, E., Iannitto, E., & Thieblemont, C. (n.d.). fIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY. Hematological oncology, 37, 224–225. http://access.bl.uk/ark:/81055/vdc_100086210627.0x000042